Oculis Holding AG (OCS)
NASDAQ: OCS · IEX Real-Time Price · USD
12.85
-0.22 (-1.68%)
May 1, 2024, 4:30 PM EDT - Market closed
Oculis Holding AG Revenue
In the year 2023, Oculis Holding AG had annual revenue of $1.05M with 7.19% growth. Revenue in the quarter ending December 31, 2023 was $220.24K with 4.67% year-over-year growth.
Revenue (ttm)
$1.05M
Revenue Growth
+21.73%
P/S Ratio
451.33
Revenue / Employee
$29,200
Employees
36
Market Cap
470.95M USD
Revenue Chart
* The company reports in CHF currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.05M | 70.55K | 7.19% |
Dec 31, 2022 | 980.65K | -74.30K | -7.04% |
Dec 31, 2021 | 1.05M | -73.46K | -6.51% |
Dec 31, 2020 | 1.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOCS News
- 2 days ago - Oculis Publishes Invitation to the Annual General Meeting - GlobeNewsWire
- 9 days ago - Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market - GlobeNewsWire
- 20 days ago - Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market - GlobeNewsWire
- 21 days ago - Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development - GlobeNewsWire
- 23 days ago - Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting - GlobeNewsWire
- 27 days ago - Oculis to Participate at Upcoming April Investor Conferences - GlobeNewsWire
- 6 weeks ago - Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress - GlobeNewsWire
- 2 months ago - Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments - GlobeNewsWire